

FATE THERAPEUTICS INC
Form 4
October 07, 2013

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Nashat Amir

2. Issuer Name and Ticker or Trading Symbol
FATE THERAPEUTICS INC
[FATE]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction (Month/Day/Year)
10/04/2013

Director 10% Owner
 Officer (give title below) Other (specify below)

C/O POLARIS VENTURE PARTNERS, 1000 WINTER STREET, SUITE 3350

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

WALTHAM, MA 02451

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
|---------------------------------|--------------------------------------|----------------------------------------------------|--------------------------------|-------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------|---|-----------------------------------------|
| | | | | (A) or (D) | Price | | | | |
| Common Stock | 10/04/2013 | | C | 1,202,459 | A | ① | 1,202,459 | I | By Polaris Venture Partners V, L.P. (3) |
| Common Stock | 10/04/2013 | | C | 255,950 | A | ② | 1,458,409 | I | By Polaris Venture Partners V, L.P. (3) |
| Common Stock | 10/04/2013 | | C | 23,436 | A | ① | 1,481,845 | I | By Polaris Venture |

Edgar Filing: FATE THERAPEUTICS INC - Form 4

| | | | | | | | | |
|--------------|------------|-------------|---------|---|------------|-----------|---|-----------------------------------------------------------------------------------------------------------------------------------------------|
| Common Stock | 10/04/2013 | C | 4,988 | A | <u>(2)</u> | 1,486,833 | I | Partners Entrepreneurs' Fund V, L.P. <u>(4)</u> By Polaris Venture Partners Entrepreneurs' Fund V, L.P. <u>(4)</u> |
| Common Stock | 10/04/2013 | C | 8,237 | A | <u>(1)</u> | 1,495,070 | I | By Polaris Venture Partners Founders' Fund V, L.P. <u>(5)</u> |
| Common Stock | 10/04/2013 | C | 1,753 | A | <u>(2)</u> | 1,496,823 | I | By Polaris Venture Partners Founders' Fund V, L.P. <u>(5)</u> |
| Common Stock | 10/04/2013 | C | 12,024 | A | <u>(1)</u> | 1,508,847 | I | By Polaris Venture Partners Special Founders' Fund V, L.P. <u>(6)</u> |
| Common Stock | 10/04/2013 | C | 2,560 | A | <u>(2)</u> | 1,511,407 | I | By Polaris Venture Partners Special Founders' Fund V, L.P. <u>(6)</u> |
| Common Stock | 10/04/2013 | <u>J(7)</u> | 123,943 | A | \$ 6 | 1,635,350 | I | By Polaris Venture Partners V, L.P. <u>(3)</u> |
| Common Stock | 10/04/2013 | <u>J(7)</u> | 2,415 | A | \$ 6 | 1,637,765 | I | By Polaris Venture Partners Entrepreneurs' Fund V, L.P. <u>(4)</u> |
| | 10/04/2013 | <u>J(7)</u> | 849 | A | \$ 6 | 1,638,614 | I | |

Edgar Filing: FATE THERAPEUTICS INC - Form 4

| | | | | | | | | |
|--------------|------------|------------------|---------|---|------|-----------|---|-----------------------------------------------------------------------|
| Common Stock | | | | | | | | By Polaris Venture Partners Founders' Fund V, L.P. <u>(5)</u> |
| Common Stock | 10/04/2013 | J ⁽⁷⁾ | 1,239 | A | \$ 6 | 1,639,853 | I | By Polaris Venture Partners Special Founders' Fund V, L.P. <u>(6)</u> |
| Common Stock | 10/04/2013 | P | 804,112 | A | \$ 6 | 2,443,965 | I | By Polaris Venture Partners V, L.P. <u>(3)</u> |
| Common Stock | 10/04/2013 | P | 15,672 | A | \$ 6 | 2,459,637 | I | By Polaris Venture Partners Entrepreneurs' Fund V, L.P. <u>(4)</u> |
| Common Stock | 10/04/2013 | P | 5,508 | A | \$ 6 | 2,465,145 | I | By Polaris Venture Partners Founders' Fund V, L.P. <u>(5)</u> |
| Common Stock | 10/04/2013 | P | 8,041 | A | \$ 6 | 2,473,186 | I | By Polaris Venture Partners Special Founders' Fund V, L.P. <u>(6)</u> |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative | 2. Conversion | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if | 4. Transaction | 5. Number of Derivative | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities |
|------------------------|---------------|--------------------------------------|-------------------------------|----------------|-------------------------|-----------------------------------------|----------------------------------------------|
|------------------------|---------------|--------------------------------------|-------------------------------|----------------|-------------------------|-----------------------------------------|----------------------------------------------|

Edgar Filing: FATE THERAPEUTICS INC - Form 4

| Security (Instr. 3) | or Exercise Price of Derivative Security | any (Month/Day/Year) | Code (Instr. 8) | Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | (Month/Day/Year) | (Instr. 3 and 4) | | | | |
|-----------------------------------------------|---------------------------------------------------|-------------------------|--------------------|-----------------------------------------------------------------------------|------------------|------------------|---------------------|--------------------|-----------------|----------------------------------|
| | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount of Number of Shares |
| Series A Convertible Preferred Stock | <u>(1)</u> | 10/04/2013 | C | | 651,806 | | <u>(1)</u> | <u>(1)</u> | Common Stock | 651,806 |
| Series A Convertible Preferred Stock | <u>(1)</u> | 10/04/2013 | C | | 12,704 | | <u>(1)</u> | <u>(1)</u> | Common Stock | 12,704 |
| Series A Convertible Preferred Stock | <u>(1)</u> | 10/04/2013 | C | | 4,465 | | <u>(1)</u> | <u>(1)</u> | Common Stock | 4,465 |
| Series A Convertible Preferred Stock | <u>(1)</u> | 10/04/2013 | C | | 6,518 | | <u>(1)</u> | <u>(1)</u> | Common Stock | 6,518 |
| Series B Convertible Preferred Stock | <u>(2)</u> | 10/04/2013 | C | | 222,677 | | <u>(2)</u> | <u>(2)</u> | Common Stock | 255,950 |
| Series B Convertible Preferred Stock | <u>(2)</u> | 10/04/2013 | C | | 4,340 | | <u>(2)</u> | <u>(2)</u> | Common Stock | 4,988 |
| Series B Convertible Preferred Stock | <u>(2)</u> | 10/04/2013 | C | | 1,525 | | <u>(2)</u> | <u>(2)</u> | Common Stock | 1,753 |
| | <u>(2)</u> | 10/04/2013 | C | | 2,227 | | <u>(2)</u> | <u>(2)</u> | | 2,560 |

| | | | | | | | | | |
|-----------------------------------------------|-----|------------|---|---------|-----|-----|-----------------|-----------------|--|
| Series B Convertible Preferred Stock | | | | | | | | Common Stock | |
| Series C Convertible Preferred Stock | (1) | 10/04/2013 | C | 550,653 | (1) | (1) | Common Stock | 550,653 | |
| Series C Convertible Preferred Stock | (1) | 10/04/2013 | C | 10,732 | (1) | (1) | Common Stock | 10,732 | |
| Series C Convertible Preferred Stock | (1) | 10/04/2013 | C | 3,772 | (1) | (1) | Common Stock | 3,772 | |
| Series C Convertible Preferred Stock | (1) | 10/04/2013 | C | 5,506 | (1) | (1) | Common Stock | 5,506 | |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|----------------------------------------------------------------------------------------------------|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| Nashat Amir C/O POLARIS VENTURE PARTNERS 1000 WINTER STREET, SUITE 3350 WALTHAM, MA 02451 | X | X | | |

Signatures

/s/ Amir Nashat 10/04/2013

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The aggregate number of shares of Issuer's Preferred Stock held by the Reporting Persons converted into Common Stock immediately prior to the closing of the Issuer's initial public offering and has no expiration date. These shares converted into Common Stock on a 1-for-1 basis.

(2) The aggregate number of shares of Issuer's Preferred Stock held by the Reporting Persons converted into Common Stock immediately prior to the closing of the Issuer's initial public offering and has no expiration date. These shares converted into Common Stock on approximately a 1-for-1.15 basis.

(3) These shares are owned directly by Polaris Venture Partners V, L.P., whose sole general partner is Polaris Venture Management Co. V, LLC ("Polaris Management"). The members of North Star Venture Management 2010 LLC are also members of Polaris Management, and as members of the general partner, they may be deemed to share voting and investment power of such shares. The Reporting Person is a member of Polaris Management and has shared voting and investment power over such shares and may be deemed the indirect beneficial owner of such shares. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.

(4) These shares are owned directly by Polaris Venture Partners Entrepreneurs' Fund V, L.P., whose sole general partner is Polaris Management. The members of North Star Venture Management 2010 LLC are also members of Polaris Management, and as members of the general partner, they may be deemed to share voting and investment power of such shares. The Reporting Person is a member of Polaris Management and has shared voting and investment power over such shares and may be deemed the indirect beneficial owner of such shares. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.

(5) These shares are owned directly by Polaris Venture Partners Founders' Fund V, L.P., whose sole general partner is Polaris Management. The members of North Star Venture Management 2010 LLC are also members of Polaris Management, and as members of the general partner, they may be deemed to share voting and investment power of such shares. The Reporting Person is a member of Polaris Management and has shared voting and investment power over such shares and may be deemed the indirect beneficial owner of such shares. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.

(6) These shares are owned directly by Polaris Venture Partners Special Founders' Fund V, L.P., whose sole general partner is Polaris Management. The members of North Star Venture Management 2010 LLC are also members of Polaris Management, and as members of the general partner, they may be deemed to share voting and investment power of such shares. The Reporting Person is a member of Polaris Management and has shared voting and investment power over such shares and may be deemed the indirect beneficial owner of such shares. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.

(7) The shares were acquired upon conversion of a convertible promissory note exempt from the definition of a derivative security because the conversion price did not become fixed until automatic conversion at the time of the closing of the Issuer's initial public offering.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.